Jefferies Boosts Arena (ARNA) Target to $20

Article Stock Quotes (1) Comments (0)

Jefferies lifted its price target on Arena Pharma (NASDAQ: ARNA) from $9 to $20 following FDA approval for Belviq.

"We believe the Belviq label is a major positive for ARNA, as it lacks a restrictive REMS or cardiovascular monitoring requirements. We remain buyers of ARNA and are raising our price target from $9 to $20."

The firm lifted FY12 EPS from $0.09 to $0.11 and FY13 EPS down from $0.10 to ($0.10).

For an analyst ratings summary and ratings history on Arena Pharma click here. For more ratings news on Arena Pharma click here.

Shares of Arena Pharma closed at $11.39 yesterday, with a 52 week range of $1.23-$13.50.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: BofA/Merrill Lynch Downgrades Cliffs Natural Resources (CLF) to Underperform
• Goldman Sachs Upgrades Mizuho Financial Group Inc. (MFG) to Buy
• AcelRx (ACRX) Target Lifted at Jefferies

Create E-mail Alert Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?